Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP338500.RAb4Mho6Dbzetv5tzaFUcj4iqEuKbOelXapIqnciLQP3U130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP338500.RAb4Mho6Dbzetv5tzaFUcj4iqEuKbOelXapIqnciLQP3U130_provenance.
• NP338531.RAd4GqQ8snjbWkmpdPbUVAAnA-LHiNmIRVzkrUTxWipm4130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP338531.RAd4GqQ8snjbWkmpdPbUVAAnA-LHiNmIRVzkrUTxWipm4130_provenance.
• NP642176.RAe0sImLIAqK-X4-KB8TWbP8sb-Zls8Qr0rN6v12vuGno130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP642176.RAe0sImLIAqK-X4-KB8TWbP8sb-Zls8Qr0rN6v12vuGno130_provenance.
• NP838379.RAbfLqA_RjdZ7PQBQvEHnxDxC2Plj8OmcRRwRLd9ORRcw130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP838379.RAbfLqA_RjdZ7PQBQvEHnxDxC2Plj8OmcRRwRLd9ORRcw130_provenance.
• NP710098.RAbOn-51OfU9cel7oBQBmsCtSGfKSeflZQrbe3aE45OXE130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP710098.RAbOn-51OfU9cel7oBQBmsCtSGfKSeflZQrbe3aE45OXE130_provenance.
• NP1005006.RARWtYRNcC9N0Em23EwrvlxgF4SCNqbPJBOJhrrGv66Io130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005006.RARWtYRNcC9N0Em23EwrvlxgF4SCNqbPJBOJhrrGv66Io130_provenance.
• NP282691.RAmBWJifwx5dSTEvSc9a0qkAtKO6wf1yygLjONt2eWUkU130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP282691.RAmBWJifwx5dSTEvSc9a0qkAtKO6wf1yygLjONt2eWUkU130_provenance.
• NP1105474.RAZCSpQWSMKRE6TDR8mHnal2OFOQO5Gdbm3m7qEwNg1Ko130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1105474.RAZCSpQWSMKRE6TDR8mHnal2OFOQO5Gdbm3m7qEwNg1Ko130_provenance.
• NP1105477.RAUz-0QgvYVRQ5pNPOTyNqYLS8juO9x_Y0EMAxcOs2r5U130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1105477.RAUz-0QgvYVRQ5pNPOTyNqYLS8juO9x_Y0EMAxcOs2r5U130_provenance.
• NP1105478.RAQnoc64gYGfUGGhxrjb8mIscKGhcIvmjrnUG2ueejY3U130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1105478.RAQnoc64gYGfUGGhxrjb8mIscKGhcIvmjrnUG2ueejY3U130_provenance.
• NP1105480.RAboqbeJ6TTxEXhUmD_9TjNyUm0Re2PPCz-i3C_jqShCs130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1105480.RAboqbeJ6TTxEXhUmD_9TjNyUm0Re2PPCz-i3C_jqShCs130_provenance.
• NP838363.RAB0z_PecT8XkkxAdPcFWrFsUOGT09E1n4kwlkMIAgtDc130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP838363.RAB0z_PecT8XkkxAdPcFWrFsUOGT09E1n4kwlkMIAgtDc130_provenance.
• NP642206.RAlc_jmU007lq1QnQ8udL2gk9TwpzNe1U7u-8gpPShu68130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP642206.RAlc_jmU007lq1QnQ8udL2gk9TwpzNe1U7u-8gpPShu68130_provenance.
• NP1105475.RAnccWsq7zl1dMfjco6TFoQhkGShGKLOkQ8iU5U6E943E130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1105475.RAnccWsq7zl1dMfjco6TFoQhkGShGKLOkQ8iU5U6E943E130_provenance.
• NP1105479.RAl5YlbG527PTRfbV2ZJjJPm0Voq5L3cj7-oiurkMc5uI130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1105479.RAl5YlbG527PTRfbV2ZJjJPm0Voq5L3cj7-oiurkMc5uI130_provenance.
• NP252543.RAxXOmCkc_0Ti2J4kYz3r6yQlPe1_8-2csbuf_7iMvZP0130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP252543.RAxXOmCkc_0Ti2J4kYz3r6yQlPe1_8-2csbuf_7iMvZP0130_provenance.
• NP252559.RA1m4bRUKKXoIs380Mu9TiwtPNpDVmTrayOGpYnQnOWYQ130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP252559.RA1m4bRUKKXoIs380Mu9TiwtPNpDVmTrayOGpYnQnOWYQ130_provenance.
• NP282818.RAGZ0r_46FabW80OEoUzYfzlVtuKHkIaa0nR2nAELw6uE130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP282818.RAGZ0r_46FabW80OEoUzYfzlVtuKHkIaa0nR2nAELw6uE130_provenance.
• NP710115.RAEahYTcn0Cjcn1POOaQv_A0ChobWl3WQGImnYRxha8UE130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP710115.RAEahYTcn0Cjcn1POOaQv_A0ChobWl3WQGImnYRxha8UE130_provenance.
• NP1105476.RAO43V207NbqICcer-ECU6H3sxEBAACC41y1tjiAUAVjM130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1105476.RAO43V207NbqICcer-ECU6H3sxEBAACC41y1tjiAUAVjM130_provenance.
• NP833671.RA_XqhefX1zHDwSLhlYFbfByrMpTGAbk1W63kH2CYmQgk130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP833671.RA_XqhefX1zHDwSLhlYFbfByrMpTGAbk1W63kH2CYmQgk130_provenance.
• NP833700.RA6SlBsWGAP8F4PqKkHsAkQ4rxFp6UMm8SMbWellHY1Jo130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP833700.RA6SlBsWGAP8F4PqKkHsAkQ4rxFp6UMm8SMbWellHY1Jo130_provenance.
• NP1005022.RAKA3mwZajoRfD0mZ_zLumyZxremU_mKtGxhfl_otkGJ4130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005022.RAKA3mwZajoRfD0mZ_zLumyZxremU_mKtGxhfl_otkGJ4130_provenance.
• NP1105481.RAxtOxSUdIcV_c0Cim0HivXpuTOD3y6qreweDhaWUKBTg130_assertion description "[Our results provide evidence for the feasibility and efficacy of the modification of HSPC with CAR as a strategy for generating multiple lineages of effector cells for immunotherapy against B-lineage malignancies to augment graft-versus-leukemia activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1105481.RAxtOxSUdIcV_c0Cim0HivXpuTOD3y6qreweDhaWUKBTg130_provenance.